

# TABLE OF CONTENTS

## Book 10

Preface .....	i
Editorial Board .....	ii
Book 10 Panel .....	iii
Disclosure of Potential Conflicts of Interest .....	ix
Continuing Education and Program Evaluation Instructions .....	x
Book 10 Post Test .....	x
Role of ACCP .....	xv

## Oncology I

### EARLY AND LOCALLY ADVANCED BREAST CANCER

Learning Objectives .....	1
Introduction .....	1
Diagnosis and Staging .....	1
Initial Examinations and Biopsy .....	1
Axillary LN Evaluation .....	1
Abbreviations in This Chapter .....	2
Prognostic and Predictive Factors .....	2
Primary Tumor Size .....	2
LN Status .....	2
Pathologic Tumor Characteristics .....	2
HR Status .....	2
HER2 Status .....	3
Proliferation Markers .....	3
Response to Systemic Therapy .....	3
Treatment of EBC and LABC .....	3
Surgery .....	3
Mastectomy .....	3
Breast Conservation Surgery .....	4
Neoadjuvant Therapy .....	4
Radiation .....	4
Adjuvant Therapy .....	4
Assessment Tools .....	5
Endocrine Surgery .....	6
Luteinizing Hormone–Releasing Hormone Analogs .....	6
Selective ER Modulators .....	6
Aromatase Inhibitors .....	6
Endocrine Therapy Summary .....	6

Chemotherapy .....	7
Taxane-Based Regimens .....	7
Anthracycline-Based Regimens .....	7
Dose Intensification Strategies .....	8
Summary .....	8
Targeted Therapy .....	10
Adverse Effects of Breast Cancer Therapy .....	10
Vasomotor Symptoms .....	10
Genitourinary Complications .....	10
Arthralgia .....	10
Bone Loss .....	11
Thromboembolic Events .....	11
Cardiac Dysfunction .....	11
Anthracyclines .....	11
Taxanes .....	11
Trastuzumab .....	11
Peripheral Neuropathies .....	12
The Role of the Pharmacist .....	12
Conclusion .....	12
Annotated Bibliography .....	12
<b>Self-Assessment Questions</b> .....	17

### METASTATIC BREAST CANCER

Learning Objectives .....	21
Overview of Metastatic Breast Cancer .....	21
Goals of Therapy in the Metastatic Setting .....	21
Sites of Metastatic Disease .....	21
Therapy Selection .....	21
Abbreviations in This Chapter .....	22
Local vs. Systemic Therapy .....	22
Hormonal vs. Chemotherapy .....	22
Monitoring Response to Therapy .....	22
Hormonal Therapy Options .....	22
Aromatase Inhibitors .....	22
Pure Antiestrogens .....	23
Luteinizing Hormone–Releasing Hormone Agonists .....	24
Drug Selection .....	25
Chemotherapy Options .....	25
Sequential vs. Combination Therapy .....	25
Anthracyclines .....	25
Taxanes .....	26
Vinorelbine, Gemcitabine, and Platinum Analogs .....	27
Drug Selection .....	27
Biologic Therapy .....	28
Trastuzumab .....	28
Bevacizumab .....	28

Other Targeted Therapies .....	29
Bisphosphonates .....	29
Brain Metastases .....	30
Conclusion .....	30
Annotated Bibliography .....	30
<b>Self-Assessment Questions .....</b>	<b>35</b>

## PHARMACOGENOMICS

Learning Objectives .....	39
Introduction .....	39
Tamoxifen .....	39
Abbreviations in This Chapter.....	40
CYP2D6 Polymorphisms .....	40
Genotype and Clinical Outcomes .....	41
Clinical Testing .....	41
Irinotecan .....	42
UGT Polymorphisms and Toxicity .....	42
Clinical Testing .....	42
Fluorouracil .....	42
DPD Polymorphisms .....	43
DPD Deficiency and Toxicity .....	43
DPD Expression and Efficacy .....	43
Clinical Testing .....	43
Mercaptopurine .....	43
TMPT Polymorphisms .....	44
TMPT Deficiency and Clinical Outcomes .....	44
TMPT Testing .....	44
Epidermal Growth Factor Inhibitors .....	45
EGFR Mutations and Efficacy .....	45
Mutations .....	45
Erlotinib .....	45
Cetuximab .....	46
Panitumumab .....	46
Clinical Testing .....	46
Tyrosine Kinase Inhibitors .....	47
BCR-ABL Mutations .....	47
Clinical Outcomes .....	47
Clinical Testing .....	48
Conclusion .....	48
Annotated Bibliography .....	48
<b>Self-Assessment Questions .....</b>	<b>51</b>

## Oncology II

### LUNG CANCER

Learning Objectives .....	57
Introduction .....	57
Prevention .....	57
Early Detection .....	57
Abbreviations in This Chapter.....	58
Clinical Presentation and Diagnosis .....	58
Classification .....	58
Non-Small Cell Lung Cancer .....	58
Staging .....	58
Prognostic Factors .....	58
Treatment .....	60
Stages I, IIA, and IIB (T2, N1) .....	60
Stages IIB (T3, N0), IIIA, and IIIB .....	60
Stage IV .....	61
Recurrent Disease .....	62
Small Cell Lung Cancer .....	62

Staging .....	62
Prognostic Factors .....	62
Treatment .....	62
Limited Stage .....	62
Extensive Stage .....	63
Prophylactic Cranial Irradiation .....	63
Recurrent Disease .....	63
Complications and Supportive Care .....	64
Elderly Patients .....	65
Patient Education .....	65
Role of the Pharmacist .....	66
Conclusion .....	66
Annotated Bibliography.....	66
<b>Self-Assessment Questions .....</b>	<b>69</b>

### RENAL CANCER

Learning Objectives .....	73
Introduction .....	73
Risk Factors .....	73
Abbreviations in This Chapter .....	74
Tumor Histology .....	74
Pathophysiology .....	74
Diagnosis .....	75
Clinical Presentation .....	75
Diagnostic Studies .....	75
Staging and Prognosis .....	76
Prognostic Factors .....	76
Management .....	76
Early Stage (Stages I–III) .....	76
Advanced Stage (Stage IV) .....	77
Surgery .....	77
Chemotherapy and Hormonal Therapy .....	77
Cytokine Therapy .....	77
Targeted Therapy .....	78
Sorafenib .....	78
Sunitinib .....	78
Temsirrolimus .....	79
Bevacizumab .....	79
Other Agents .....	79
Special Populations .....	79
Non-Clear Cell Histology Tumors .....	79
Presence of Brain Metastasis .....	80
Absence of Nephrectomy .....	80
Noncytokine Refractory Tumors .....	80
Evolving Therapies .....	81
Supportive Care Issues .....	81
Conclusion .....	82
Annotated Bibliography .....	82
<b>Self-Assessment Questions .....</b>	<b>85</b>

### SUPPORTIVE CARE

Learning Objectives .....	89
Introduction .....	89
Anticoagulation in Patients with Cancer .....	89
Abbreviations in This Chapter .....	90
Fatigue and Anemia .....	90
Iron Therapy.....	91
ESA Therapy.....	91
Tumor Lysis Syndrome .....	92
Patient Adherence to Therapy .....	93
Natural Products and Care of Patients with Cancer .....	93

Pain Management .....	94
Newer Agents .....	94
Patient Education .....	95
Antiemetic Therapy .....	96
Clinical End Points .....	96
New Antiemetic Agent Options .....	96
Antiemetic Therapy Guidelines .....	96
Breakthrough and Refractory Emesis .....	97
Quality Patient Care .....	97
Annotated Bibliography.....	98
<b>Self-Assessment Questions</b> .....	101

## **Oncology III**

### **PEDIATRIC LEUKEMIAS**

Learning Objectives .....	107
Introduction .....	107
Acute Lymphoblastic Leukemia .....	107
Epidemiology .....	107
Genetics .....	107
Pathophysiology .....	107
Abbreviations in This Chapter .....	108
Clinical Presentation .....	108
Diagnosis .....	108
Classification .....	108
Prognostic Factors .....	109
Treatment .....	109
Remission Induction .....	109
Intensification (Consolidation) Therapy .....	110
Continuation (Maintenance) and Reinduction Therapy .....	110
Reintensification Therapy .....	110
CNS Therapy .....	110
Pharmacogenetics of Therapy .....	111
Hematopoietic Stem Cell Transplantation .....	111
Treatment of Specific Risk Groups .....	111
Infant ALL .....	111
Down Syndrome .....	111
Relapsed ALL .....	111
Acute Myeloid Leukemia .....	111
Epidemiology and Risk Factors .....	111
Clinical Presentation .....	112
Diagnosis, Classification, and Prognostic Factors .....	112
Treatment .....	112
Induction Therapy .....	112
Consolidation (Intensification) Therapy .....	113
CNS Prophylaxis .....	113
Antimicrobial Prophylaxis .....	113
Relapsed AML .....	113
Treatment-Related AML .....	113
Long-Term Complications	
After Leukemia Therapy .....	114
Cardiac Toxicity .....	114
Endocrinopathies .....	114
Thyroid Dysfunction .....	114
Gonadal Dysfunction .....	114
Obesity .....	114
Skeletal Abnormalities .....	114
Secondary Malignancies .....	115
The Role of the Pharmacist .....	115

Annotated Bibliography .....	115
<b>Self-Assessment Questions</b> .....	119

### **PEDIATRIC BRAIN NEOPLASMS**

Learning Objectives .....	121
Introduction .....	121
Medulloblastoma .....	121
Abbreviations in This Chapter .....	122
Chromosomal Aberrations and Molecular Biology .....	122
Clinical Symptoms .....	122
Therapy .....	122
Glioma .....	124
Low-Grade Gliomas .....	124
Clinical Symptoms .....	124
Therapy .....	124
High-Grade Gliomas .....	125
Clinical Symptoms .....	125
Therapy .....	125
Ependymoma .....	126
Clinical Symptoms .....	126
Therapy .....	126
Long-term Complications Associated with Therapy for Pediatric Brain Neoplasms .....	127
The Role of the Pharmacist .....	128
Annotated Bibliography .....	129
<b>Self-Assessment Questions</b> .....	131

### **CENTRAL NERVOUS SYSTEM TUMORS**

Learning Objectives.....	135
Primary Central Nervous System Tumors .....	135
Pathology .....	135
Epidemiology .....	135
Risk Factors .....	135
Abbreviations in This Chapter.....	136
Molecular Pathogenesis .....	136
Clinical Presentation .....	136
Diagnosis .....	136
Treatment Options .....	136
Surgery .....	136
Radiation .....	137
Chemotherapy .....	137
Barriers to Therapy.....	137
Anaplastic Tumors.....	137
Standard of Care for Newly Diagnosed GBM .....	137
Carmustine-Coated Implantable Wafers .....	137
Temozolomide .....	138
Recurrent GBM .....	138
Future Directions .....	139
Secondary (Metastatic) CNS Tumors .....	139
Epidemiology .....	139
Clinical Presentation .....	139
Prognosis .....	139
Therapeutic Options .....	140
Radiation .....	140
Surgery .....	140
Chemotherapy .....	140
Complications Associated with Brain Metastases .....	140
Vasogenic Edema .....	140
Seizures .....	140
Venous Thromboembolism .....	141

Role of the Pharmacist .....	141
Conclusion .....	141
Annotated Bibliography .....	141
<b>Self-Assessment Questions</b> .....	<b>145</b>

**MYELOYDYSPLASTIC SYNDROME AND  
CHRONIC MYELOID LEUKEMIA**

Learning Objectives .....	147
Myelodysplastic Syndrome .....	147
Prognostic Features .....	147
Abbreviations in This Chapter.....	148
Goals of Therapy .....	148
Historical Perspective .....	148
Outcomes Definitions .....	148
Therapeutic Options .....	148
Supportive Care .....	148
Growth Factors .....	148
Iron Chelation .....	149
DNA Methyltransferase Inhibitors .....	149
Azacitidine .....	150
Decitabine .....	151
Lenalidomide .....	151
Allogeneic SCT .....	151
Conclusion .....	151
Chronic Myeloid Leukemia .....	152
Monitoring Responses .....	152
Treatment .....	152
Imatinib Mesylate .....	152
Mechanisms of Imatinib Resistance .....	153
Therapeutic Options for Imatinib Resistance .....	154
Increased Imatinib Dosing .....	154
Dasatinib .....	154
Nilotinib .....	154
Allogeneic SCT .....	154
Conclusion .....	155
Role of the Pharmacist .....	155
Annotated Bibliography .....	155
<b>Self-Assessment Questions</b> .....	<b>159</b>